Table 4 |
||||
|
Predictors of first-line therapy prescription and co-prescription of concomitant antibiotics1,2 |
||||
|
Prescription of first-line therapy (ART-AQ) |
Antibiotic use |
|||
|
|
||||
|
Adjusted odds ratio [95% CI] |
p-value |
Adjusted odds ratio [95% CI] |
p-value |
|
|
|
||||
|
Age group |
||||
|
<5 |
1.0 |
1.0 |
||
|
5–12 |
3.6 [2.6–4.9] |
<0.001 |
- |
- |
|
13–59 |
2.5 [2.0–3.1] |
<0.001 |
0.53 [0.44–0.64] |
<0.001 |
|
≥60 |
2.6 [1.8–3.9] |
<0.001 |
0.55 [0.37–0.83] |
0.004 |
|
Facility type |
||||
|
Non-government |
1.0 |
- |
- |
|
|
Government |
6.3 [3.6–11.1] |
<0.001 |
- |
- |
|
Mode of diagnosis |
||||
|
Presumptive |
1.0 |
1.0 |
||
|
Laboratory confirmed |
9.7 [5.2–18.2] |
<0.001 |
0.68 [0.41–1.1] |
0.13 |
|
Anti-malarial treatment prescribed |
||||
|
Combination therapy (ART-AQ) |
- |
- |
1.0 |
|
|
Combination therapy (Other ACT) |
- |
- |
- |
- |
|
Monotherapy (Artemisinin based) |
- |
- |
1.2 [0.97–1.4] |
0.11 |
|
Monotherapy (Non-artemisinin) |
- |
- |
1.4 [1.1–1.9] |
0.02 |
|
|
||||
|
1 Gender was not significant in either of the final models 2 N = 2,535 for both models. Patients with unknown age (n = 31) and/or unknown mode of diagnosis (n = 272) were excluded. |
||||
|
Dodoo et al. Malaria Journal 2009 8:2 doi:10.1186/1475-2875-8-2 |
||||
